Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 12/20 | 0.65 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.64 |
| ▸ | BRD4 | O60885 | 7/20 | 0.64 |
| ▸ | DCLK1 | O15075 | 6/20 | 0.64 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.64 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16982790 | 0.94 | LRRK2 (0.73) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL18313550 | 0.85 | MAPK7 (0.67) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL16982791 | 0.85 | LRRK2 (0.70) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL16065732 | 0.84 | MAPK7 (0.89) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL16974436 | 0.82 | MAPK7 (0.53) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL16980127 | 0.79 | LRRK2 (0.76) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL616339 | 0.79 | MAPK7 (1.00) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL22605975 | 0.79 | LRRK2 (0.76) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL18313552 | 0.78 | MAPK7 (0.78) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL616761 | 0.78 | LRRK2 (1.00) | MAPK7LRRK2BRD4DCLK1BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016201370-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-15 | — | — | WO | disclosed |